Somerville Kurt F Sells 594 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Somerville Kurt F lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 27,178 shares of the biopharmaceutical company’s stock after selling 594 shares during the quarter. Somerville Kurt F’s holdings in Pfizer were worth $1,065,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Morgan Stanley lifted its stake in Pfizer by 2.4% in the 2nd quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after purchasing an additional 1,071,897 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Pfizer by 2.6% during the third quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock worth $1,627,320,000 after purchasing an additional 1,158,147 shares during the period. Nuveen Asset Management LLC increased its position in Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after buying an additional 34,544,423 shares during the last quarter. California Public Employees Retirement System increased its position in Pfizer by 5.3% during the second quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock worth $1,004,428,000 after buying an additional 1,159,857 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in Pfizer by 1.7% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 22,492,988 shares of the biopharmaceutical company’s stock valued at $808,173,000 after buying an additional 369,603 shares during the period. 70.21% of the stock is owned by institutional investors and hedge funds.

Pfizer stock opened at $40.67 on Thursday. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $44.56. The stock’s 50 day moving average is $38.90 and its 200-day moving average is $38.18. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $221.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 4.24 and a beta of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The firm’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period last year, the firm posted $0.78 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 31st will be issued a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a yield of 3.74%. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. Pfizer’s dividend payout ratio is currently 48.00%.

A number of analysts have recently issued reports on the company. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America assumed coverage on Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 price objective on shares of Pfizer in a research report on Wednesday, November 6th. Finally, Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Pfizer currently has a consensus rating of “Hold” and an average target price of $43.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: S&P 500 Index

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.